6.7068

3.64% -0.2532

After Hours: 6.71 0.0032 +0.05%

Forte Biosciences Inc (FBRX)

Overview News Price History Option Chain Financials Discussions Forecast

Forte Biosciences Inc stock is traded at $6.7068, with a volume of 28,908. It is down -3.64% in the last 24 hours and down -21.19% over the past month. Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).

Previous Close:

$6.96

Open:

$6.96

24h Volume:

28,908

Relative Volume:

0.81

Market Cap:

$46.14M

Revenue:

Net Income/Loss:

$-31.48M

P/E Ratio:

-6.4488

EPS:

-1.04

Net Cash Flow:

$-28.71M

1W Performance:

-8.63%

1M Performance:

-21.19%

6M Performance:

+43.35%

1Y Performance:

-63.70%

1-Day Range:

$6.06

$6.96

1-Week Range:

$4.90

$7.6646

52-Week Range:

$4.11

$28.68

Forte Biosciences Inc Stock (FBRX) Company Profile

Name

Forte Biosciences Inc

Sector

Healthcare (1154)

Industry

Biotechnology (677)

Phone

(310) 618-6994

Address

3060 PEGASUS PARK DRIVE, DALLAS, CA

Employee

Twitter

Next Earnings Date

2024-11-11

Latest SEC Filings

FBRX's Discussions on Twitter

Compare FBRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FBRX Forte Biosciences Inc	6.7068	46.14M	0	-31.48M	-28.71M	-1.04
VRTX Vertex Pharmaceuticals Inc	493.84	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	602.64	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	614.76	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.56	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	244.90	24.70B	3.81B	-644.79M	-669.77M	-6.24

Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-21-25	Initiated	TD Cowen	Buy
Apr-08-24	Upgrade	Ladenburg Thalmann	Neutral → Buy
Sep-20-21	Upgrade	Chardan Capital Markets	Sell → Buy
Sep-03-21	Downgrade	B. Riley Securities	Buy → Neutral
Sep-03-21	Downgrade	Chardan Capital Markets	Buy → Sell
Sep-03-21	Downgrade	Ladenburg Thalmann	Buy → Neutral
Sep-03-21	Downgrade	Truist	Buy → Hold
May-14-21	Initiated	B. Riley Securities	Buy
Mar-26-21	Initiated	Citigroup	Buy
Aug-28-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Aug-25-20	Initiated	Truist	Buy

View All

Forte Biosciences Inc Stock (FBRX) Latest News

Apr 18, 2025

Forte Biosciences sets Annual Meeting for May 29 By Investing.com - Investing.com Canada

Apr 18, 2025

Forte Biosciences sets Annual Meeting for May 29 - Investing.com Australia

Apr 18, 2025

Pre-market Movers: OPTN, WINT, AKBA, GCTK... - RTTNews

Apr 18, 2025

Traders Buy High Volume of Call Options on Forte Biosciences (NASDAQ:FBRX) - Defense World

Apr 18, 2025

Apr 17, 2025

Mr. Ethan Billings recommends paying close attention to biotech stocks - FinancialContent

Apr 17, 2025

Apr 07, 2025

Forte Biosciences Sees Unusually Large Options Volume (NASDAQ:FBRX) - Defense World

Apr 03, 2025

Chardan Capital Issues Pessimistic Forecast for Forte Biosciences (NASDAQ:FBRX) Stock Price - Defense World

Apr 03, 2025

Apr 02, 2025

Chardan Adjusts Price Target on Forte Biosciences to $61 From $64, Maintains Buy Rating - MarketScreener

Apr 02, 2025

Forte Biosciences Reports 2024 Progress and Financials - TipRanks

Apr 02, 2025

Apr 01, 2025

Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans? - Yahoo

Apr 01, 2025

Mar 31, 2025

Forte's Celiac Treatment Shows Promise: Zero Dropouts and $58.4M War Chest - Stock Titan

Mar 31, 2025

Forte Biosciences, Inc. Announces Results and Provides Clinical Update - Bluefield Daily Telegraph

Mar 31, 2025

Mar 28, 2025

Forte Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 28, 2025

Forte Biosciences Inc Files For Mixed Shelf Of Up To $300 MillionSEC Filing - MarketScreener

Mar 28, 2025

Forte Biosciences, Inc. SEC 10-K Report - TradingView

Mar 28, 2025